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A B S T R A C T
Background
Acute bacterial meningitis remains a disease with high mortality andmorbidity rates. However, with prompt and adequate antimicrobial
and supportive treatment, the chances for survival have improved, especially among infants and children. Careful management of fluid
and electrolyte balance is an important supportive therapy. Both over- and under-hydration are associated with adverse outcomes. This
is the latest update of a review first published in 2005 and updated in 2008 and 2014.
Objectives
To evaluate treatment of acute bacterial meningitis with differing volumes of initial fluid administration (up to 72 hours after first
presentation) and the effects on death and neurological sequelae.
Search methods
For this 2016 update we searched the following databases up to March 2016: the Cochrane Acute Respiratory Infections Group’s
Specialised Register, CENTRAL, MEDLINE, CINAHL, Global Health, and Web of Science.
Selection criteria
Randomised controlled trials (RCTs) of differing volumes of fluid given in the initial management of bacterial meningitis were eligible
for inclusion.
Data collection and analysis
All four of the original review authors extracted data and assessed trials for quality in the first publication of this review (one author,
ROW, has passed away since the original review; see Acknowledgements). The current authors combined data for meta-analysis using
risk ratios (RRs) for dichotomous data or mean difference (MD) for continuous data. We used a fixed-effect statistical model. We
assessed the overall quality of evidence using the GRADE approach.
Main results
We included three trials with a total of 420 children; there were no trials in adult populations. The largest of the three trials was
conducted in settings with high mortality rates and was judged to have low risk of bias for all domains, except performance bias
which was high risk. The other two smaller trials were not of high quality.The meta-analysis found no significant difference between
the maintenance-fluid and restricted-fluid groups in number of deaths (RR 0.82, 95% confidence interval (CI) 0.53 to 1.27; 407
participants; low quality of evidence) or acute severe neurological sequelae (RR 0.67, 95% CI 0.41 to 1.08; 407 participants; low
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quality of evidence). However, when neurological sequelae were defined further, there was a statistically significant difference in favour
of the maintenance-fluid group for spasticity (RR 0.50, 95% CI 0.27 to 0.93; 357 participants); and seizures at both 72 hours (RR
0.59, 95% CI 0.42 to 0.83; 357 participants) and 14 days (RR 0.19, 95% CI 0.04 to 0.88; 357 participants). There was very low
quality of evidence favouring maintenance fluid over restrictive fluid for chronic severe neurological sequelae at three months follow-
up (RR 0.42, 95% CI 0.20 to 0.89; 351 participants).
Authors’ conclusions
The quality of evidence regarding fluid therapy in children with acute bacterial meningitis is low to very low and more RCTs need to
be conducted. There is insufficient evidence to guide practice as to whether maintenance fluids should be chosen over restricted fluids
in the treatment of acute bacterial meningitis.
P L A I N L A N G U A G E S U M M A R Y
Fluids for people with acute bacterial meningitis
Review question
Why is the effect of differing volumes of initial fluid administration on death and various neurological sequelae in people with acute
bacterial meningitis important?
Background
Bacterial meningitis is an infection of the fluid in the spinal cord and surrounding the brain. Antibiotics are prescribed as treatment.
Supportive care includes other drugs and the regulation of fluid intake. There has been disagreement about whether fluids should be
restricted or unrestricted as there are potential risks from giving too much fluid (brain swelling) as well as too little fluid (shock).
Study characteristics
The evidence is current toMarch 2016. We did not find any trials in adult populations and included three trials involving 420 children.
All trials were set in countries where death rates for meningitis are high. In one study no funding source was mentioned. The remaining
two studies were funded jointly by pharmaceutical concerns with government agencies and a charitable agency.
Key results
No studies reported important healthcare outcomes such as duration of hospital stay, raised intracranial pressure, or status epilepticus.
An adverse effect in children with restricted fluid intake was that they were less likely to have low levels of sodium in their blood and
therefore they would experience greater reductions in body fluids. An adverse effect of unrestricted fluid administration was reported in
one study as short-term swelling of the face and low blood sodium levels one to two days after fluids were started, although the largest
study found no difference in blood sodium levels.
The review found limited evidence from these trials in support of not restricting fluids in settings with high mortality rates. There is
no evidence to guide clinicians about fluid therapy in adult patients with acute bacterial meningitis. There is a need for more research
on these aspects in the future.
Quality of the evidence
Analysis of available trials found low quality evidence that there is no significant difference between maintenance versus restrictive fluid
regimens for the outcome of death and acute severe neurological complications. There was also some evidence favouring maintenance
fluid therapy over restricted fluids for chronic severe neurological events at three months follow-up, but the quality was very low.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Maintenance fluids versus restricted fluids for acute bacterial meningitis
Patient or population: paediatric pat ients with acute bacterial meningit is
Settings: hospital inpat ient department
Intervention: maintenance f luids
Comparison: restricted f luids
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
Restricted fluids Maintenance fluids
Death - all participants Study population RR 0.82
(0.53 to 1.27)
407
(2 studies)
⊕⊕©©
low1,2
186 per 1000 153 per 1000
(99 to 237)
Moderate risk population
213 per 1000 175 per 1000
(113 to 271)
Severe neurological seque-
lae - acute (within the first
4 weeks)
Study population RR 0.67
(0.41 to 1.08)
407
(2 studies)
⊕⊕©©
low1,2
176 per 1000 118 per 1000
(72 to 191)
Moderate risk population
252 per 1000 169 per 1000
(103 to 272)
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Severe neurological seque-
lae - chronic (after the first
4 weeks)
Study population RR 0.42
(0.20 to 0.89)
351
(1 study)
⊕©©©
very low3,4
121 per 1000 51 per 1000
(24 to 108)
Moderate risk population
121 per 1000 51 per 1000
(24 to 108)
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: conf idence interval; RR: risk rat io.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 Total number of events is small and 95%CI around pooled est imate includes both appreciable benef it and harms.
2 Duke 2002 and Singhi 1995 both were deemed to have high risk of bias for blinding. However, this would not have any ef fect
on outcome assessment for the outcome of death and acute severe neurological sequelae. Singhi 1995 was deemed at high
risk for report ing bias but we did not downgrade for risk of bias because sensit ivity analyses did not change ef fect est imates
signif icant ly.
3 Duke 2002 - high risk of bias due to improper blinding would af fect outcome assessment for chronic severe neurological
sequelae.
4 Total number of events is not large enough for precision.
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B A C K G R O U N D
Description of the condition
Acute bacterial meningitis remains a disease with high mortality
and morbidity rates. The outcome in individuals with bacterial
meningitis is correlated with many factors, including the age of
the person, time and clinical stability before effective antibiotic
treatment is begun, type of micro-organism, number of bacteria
or quantity of active bacterial products in the cerebrospinal fluid
(CSF) at the time of diagnosis, intensity of the host’s inflammatory
response, and time elapsed to sterilise CSF cultures (Feldman
1977; Mustafa 1990; Saez-Llorens 1990; Waage 1987).
Description of the intervention
The highest rates of mortality and morbidity occur in the neona-
tal period and in the elderly. Nearly one in four adults with the
illness will die, and many survivors sustain neurological deficits
(Bohr 1983; Pfister 1993). Bacterial meningitis causes more than
100,000 deaths worldwide each year in infants and young chil-
dren (Duke 1998). A 1993 meta-analysis examined the overall
and organism-specific frequencies of death and persistent neuro-
logical sequelae in children two months to 19 years of age (Baraff
1993). A total of 4920 children with acute bacterial meningitis
were included in 45 reports that met the inclusion criteria. Chil-
dren described in the 19 reports of prospectively-enrolled cohorts
from high-income countries had lowermortality than the children
included in trials from low-income countries (4.8% versus 8.1%)
and weremore likely to have no sequelae (82.5% versus 73.9%). A
further study that examined the long-term consequences of having
meningitis during the first year of life found that 1.8% of children
died within five years (Bedford 2001). Not only did almost a fifth
of children with meningitis have a subsequent permanent, severe,
or moderately severe disability, but subtle deficits were also more
prevalent.
How the intervention might work
The chances for survival are improved with prompt and adequate
antimicrobial and supportive treatment, especially in infants and
children, for whom case fatality rates have been reduced to less
than 10% for bacterial meningitis and less than 5% for meningo-
coccal meningitis (Saez-Llorens 2003). Two Cochrane Reviews
examine the effectiveness and safety of steroids and different an-
tibiotic regimens, respectively, which are used in the treatment of
acute bacterial meningitis (Brouwer 2015; Prasad 2011).
Careful management of fluid and electrolyte balance is also impor-
tant in the treatment of meningitis. Over- or under-hydration are
associated with adverse outcomes. Fluid restriction in the initial
management of meningitis in children has been widely advocated
(Conner 1980; Feigin 1992). However, this has also been chal-
lenged (Conner 1980; Powell 1990; Singhi 1995). The practice of
fluid restriction is based on reports of hyponatraemia (lower than
normal concentration of sodium in the extracellular fluid/blood)
that is attributed to increased concentrations of circulating antidi-
uretic hormone (ADH; a hormone that prevents excretion of water
from the body). Over 50% of children have hyponatraemia at the
time of admission (Kaplan 1983). There are associations between
the degree of hyponatraemia and the presence of seizures and sever-
ity of acute disease, and adverse neurodevelopmental outcomes
(Feigin 1977). These findings have subsequently been linked with
a high incidence of cerebral oedema (swelling of the brain) in those
who die from acute bacterial meningitis (Conner 1980; Dodge
1965; Williams 1964), and it has been suggested that inappro-
priately increased concentrations of ADH lead to water retention,
which in turn exacerbates cerebral swelling. Some researchers have
concluded that fluid restriction will avoid exacerbating cerebral
oedema and may improve neurological outcome (Brown 1994).
However, clinical dehydration has also been found in children
with acute bacterial meningitis without any accompanying signif-
icant risk of mortality (Duke 1998). It has also been found that
in children who received maintenance fluid plus replacement of
volume deficits, the high ADH concentrations normalised over
24 hours; in those who were restricted to two-thirds maintenance
fluids, ADH concentrations remained high (Powell 1990). The
conclusion from this was that ADH concentrations are increased
in children with meningitis because of hypovolaemia (a decrease
in the volume of circulating blood) and only become normal when
sufficient sodium and fluid are given.
Why it is important to do this review
Although it is widely accepted that hyponatraemia is a marker of
severe disease in childhood bacterial meningitis, there are different
opinions regarding the cause of hyponatraemia at the time of pre-
sentation. If dehydration, rather than inappropriately increased
antidiuresis, is the major factor in the pathogenesis of hypona-
traemia in meningitis, then the rationale for fluid restriction is
open to question.
O B J E C T I V E S
To evaluate treatment of acute bacterial meningitis with differing
volumes of initial fluid administration (up to 72 hours after first
presentation) and the effects on death and neurological sequelae.
M E T H O D S
5Fluid therapy for acute bacterial meningitis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs) examining the effectiveness
of different volumes of initial fluid administration in the treat-
ment of acute bacterial meningitis were eligible for inclusion. We
planned to consider trials of fluids administered to treat shock at
presentation but we found no such trials.
Types of participants
All age groups with a diagnosis of acute bacterial meningitis, made
either by clinical diagnosis or culture of cerebrospinal fluid (CSF)
obtained at lumbar puncture, were eligible for inclusion.
Types of interventions
1. Fluid administered in the initial treatment of acute bacterial
meningitis; irrespective of route of administration, type, or
volume of fluid.
2. Comparisons of the initial volume of fluid administered in
the treatment of acute bacterial meningitis, irrespective of route
of administration, or type of fluid, or duration of fluid restriction.
Types of outcome measures
Primary outcomes
1. Death
2. Short-term (within the first four weeks of illness) and long-
term (persisting after the first four weeks of illness) neurological
sequelae
Secondary outcomes
1. Oedema (including cerebral)
2. Total body water
3. Extracellular water
4. Serum and urinary sodium
5. Plasma and urinary osmolality
6. Duration of hospital stay
7. Raised intracranial pressure
8. Status epilepticus
Search methods for identification of studies
Electronic searches
For this 2016 update we searched:
• the Cochrane Acute Respiratory Infections Group’s
Specialised Register (21 March 2016);
• the Cochrane Central Register of Controlled Trials
(CENTRAL; 2016, Issue 2) in the Cochrane Library using the
search strategy in Appendix 1;
• MEDLINE (November 2013 to 21 March 2016; search
strategy in Appendix 2);
• CINAHL (November 2013 to 21 March 2016; search
strategy in Appendix 3);
• Global Health (November 2013 to 21 March 2016; search
strategy in Appendix 4); and
• Web of Science (2013 to 21 March 2016; search strategy in
Appendix 5).
For the previous update in 2014 we searched various databases
in November 2013 (Appendix 6, Appendix 7, Appendix 8, Ap-
pendix 9, Appendix 10). The MEDLINE search was combined
with theCochraneHighly Sensitive Search Strategy for identifying
randomised trials in MEDLINE: sensitivity- and precision-max-
imising version (2008 revision) (Lefebvre 2011). Details about
search strategies for earlier versions of the review are available in
Appendix 11 and Appendix 12.
Searching other resources
We searched references from included trials and contacted trial
authors where necessary. In addition, we contacted experts in the
field for unpublished works. We searched the following trial reg-
isters.
• ClinicalTrials.gov (clinicaltrials.gov; searched March 2016);
• World Health Organization International Clinical Trials
Registry Platform (who.int/ictrp/en; searched 6 November
2013).
Inmuch earlier versions theNationalHealth andMedical Research
Council (NHMRC) Clinical Trials Register (www.nhmrc.gov.au)
and meta-register of controlled trials (www.isrctn.com ) was
searched. We attempted to contact authors of all identified trials,
whether open or unpublished. We sought publications in the liter-
ature that described, or may have described, the use of fluid ther-
apy for the treatment of acute bacterial meningitis. We applied no
language or publication status restrictions. We searched the cita-
tion lists of relevant publications, review articles, and abstracts of
scientific meetings, and included both published and unpublished
studies.
Data collection and analysis
Selection of studies
For this 2016 update, two review authors (SB, IM) independently
screened all the search results for consideration of inclusion as per
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eligibility criteria based on title, abstract, and key words initially,
and then after accessing full-texts. Any disagreements were to be
resolved by consensus, with the Review Group Editor acting as
an arbiter. For previous versions of this review, two review au-
thors (HB, IM) undertook study selection after running the search
strategies outlined above. Both review authors had independently
assessed whether the studies met the inclusion criteria; any dis-
crepancies then were to be resolved by a third author (ROW, see
Acknowledgements) but this proved unnecessary.
We sought further information from the trial authors where papers
contained insufficient information to make a decision about eligi-
bility. We had to do this for two studies which we excluded based
on these communications (Characteristics of excluded studies).
Data extraction and management
We collected information regarding location of the study, meth-
ods of the study (as per quality assessment checklist), participant
characteristics (age range, eligibility criteria), types of interven-
tions and outcomes for each included trial. Where possible, we
sought missing data from the trial authors. Four review authors
had previously (IM, HB, MS , ROW) independently performed
data extraction. Any discrepancies were to be resolved by discus-
sion but this proved unnecessary.
Assessment of risk of bias in included studies
We assessed the risk of bias in the included studies using the cri-
teria described in the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011). Two review authors independently
extracted information about selection bias (random sequence gen-
eration and allocation concealment), detection bias (blinding of
outcome assessment), attrition bias (incomplete outcome data),
reporting bias (selective reporting), sample size, and exclusions af-
ter randomisation, and any other sources of bias .
Measures of treatment effect
We analysed each dichotomous outcome for effect in terms of a
risk ratio (RR) with a 95% confidence interval (CI) and combined
the outcomes for meta-analysis using Review Manager 5 software
(RevMan 2014). Where data were sufficient, we calculated a sum-
mary statistic for each outcome using a fixed-effect model. We
analysed continuous outcomes as mean differences (MDs) be-
tween groups and 95% CIs. Where data were sufficient, we used
a fixed-effect approach in the meta-analysis.
There were two kinds of effect estimates in our study. One, where
only a single study contributed to the outcome, in which case a
fixed-effect model was appropriate, and two, those pooled esti-
mates where there was more than one study (two studies) and little
evidence of heterogeneity was detected. Therefore, a fixed-effect
model was used.
Unit of analysis issues
We did not include any studies with non-standard designs. The
comparisons under consideration would not lend themselves to
cluster-randomised or other similar designs.
Dealing with missing data
Where thereweremissing participants due to dropout, we searched
for the use of an intention-to-treat (ITT) analysis by the trial
authors and reported this in the review. Where there were missing
statistics (such as, standard deviations or correlation coefficients)
that made analysis impossible, we approached the trial authors.
Where there remained missing data, we report this in the review.
Assessment of heterogeneity
Wedetermined statistical heterogeneity by a combination of visual
inspection of graphs of RRs as well as using the I² statistic (Higgins
2003), and the Chi² test.
Assessment of reporting biases
We had intended to investigate for publication bias and other
reporting biases initially by the use of funnel plots. However, as
there were only three included studies, we were unable to do so.
Data synthesis
We entered and analysed all data using ReviewManager 5 software
(RevMan 2014). We discuss methods of analyses for subgroup
analysis, investigation of heterogeneity, and sensitivity analyses in
the relevant sections.
GRADE and ’Summary of findings’ table
For the 2014 update, two authors (SB, IM) used the GRADE
approach to interpret the findings (Schunemann 2011). We used
the GRADE profiler software (GRADEpro GDT 2014), and im-
ported data fromRevMan 2014 to create Summary of findings for
the main comparison containing the following outcomes: death,
and acute and chronic severe neurological sequelae. We used the
five GRADE considerations (study limitations, consistency of ef-
fect, imprecision, indirectness, and publication bias) to assess the
quality of a body of evidence as it relates to the studies which
contribute data to the meta-analyses for the prespecified outcomes
(Atkins 2004).We used methods and recommendations described
in Section 8.5 and Chapter 12 of the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011). Summary of
findings for the main comparison provides information about the
overall quality of evidence from trials, the magnitude of effect of
the interventions, as well as the sum of the available data for the
primary outcomes. We justified all decisions to down- or upgrade
the quality of studies using footnotes, and we made comments to
aid the reader’s understanding of the review where necessary.
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Subgroup analysis and investigation of heterogeneity
We had planned that if there were a sufficient number of trials of
adequate size, with the required information recorded in the trial
publication, we would conduct subgroup analyses by:
• age;
• volume of fluid administered;
• organism causing the meningitis;
• hypoperfusion status at enrolment; and
• clinical diagnosis versus laboratory-confirmed diagnosis.
We assessed clinical heterogeneity by establishing the overall mor-
tality rates and duration of symptoms, where possible. We used
this to distinguish between participants studied in different health
settings. We did not deem meta-analysis appropriate where it was
evident that studies were undertaken in different health contexts.
Sensitivity analysis
We had planned to perform an a priori sensitivity analysis on re-
sults to look at the possible contribution of differences in method-
ological quality, but we were unable to do this due to the paucity
of trials.
R E S U L T S
Description of studies
Results of the search
For this 2016 update we identified 824 records (CENTRAL =
128, CINAHL = 29, Global Health = 298, MEDLINE = 221,
Web of Science = 133, ClinicalTrials.gov = 14, reference search-
ing = 1). After removing duplicates (n = 139), we screened 685
records. We recovered full-texts for three of them (Pelkonen 2011;
Roine 2014; van Paridon 2015), but we did not find any to be
eligible for inclusion. Reasons for exclusion are documented in the
Characteristics of excluded studies table.
For the 2014 update, with duplicates removed (including dupli-
cates of the records sent in 2010) there were 496 search results. We
removed animal studies (n = 49) and screened 447 search results
(Maconochie 2014). We excluded 445 search results on the basis
of title or abstract and two on the basis of full-text inspection. We
did not find any studies in the grey literature. Reasons for exclu-
sion are given in the Characteristics of excluded studies table.
In the 2011 update, six abstracts identified in the search initially
appeared to fit the inclusion criteria for the review (Maconochie
2011). After obtaining the full papers, we excluded three of these,
leaving three trials eligible for inclusion (420 children). In the 2008
update, we retrieved 105 records from the search of the electronic
databases but did not find any new included trials for inclusion
(Maconochie 2008).
Included studies
1. Trial design characteristics
Volume and constitution of fluid
TheDuke 2002 trial comparedmilk-based fluids delivered at 60%
of that required for maintenance fluids with 100% of normal
maintenance fluids. Maintenance fluids were defined as “100 ml/
kg/day for the first 10 kg of body weight, 50 ml/kg for the second
10 kg, and 20 ml/kg for over 20 kg”. The milk-based fluids com-
prised expressed breast milk or other milk feed given via a naso-
gastric tube for at least 48 hours, or longer with reduced conscious
state, convulsions, impaired upper airway reflexes, or persistent
respiratory distress. Normal maintenance fluids (defined as above)
of a solution containing 0.45% sodium chloride and 5% dextrose
plus 10 mmol/L of potassium chloride per litre were delivered in-
travenously for at least the first 48 hours.
The Powell 1990 trial compared two-thirds of required mainte-
nance fluids (similarly defined as “100 ml/kg for the first 10 kg
of body weight, plus 50 ml/kg for the next 10 kg (10 kg to 20
kg), plus 20 ml/kg for each kilogram in excess of 20 kg”) with
full maintenance fluids, plus replacement fluids for any estimated
deficit over 24 hours. Rehydration was begun by administering
10 ml/kg or 15 ml/kg by rapid intravenous infusion. Fluids were
given intravenously with the composition determined by the at-
tending consultant.
The Singhi 1995 trial compared restricted fluids at 65% of the
calculated maintenance fluid requirement with maintenance fluid
requirements (110 ml/kg for first 10 kg, 50 ml/kg for next 10 kg
and 25 ml/kg for subsequent weight), both given intravenously.
The restricted fluids comprised one-fifth normal saline in 5% dex-
trose for 24 hours, followed by “a gradual liberalisation at a rate of
10 ml/kg over eight hours, if, after 24 hours of hospital stay, the
serum sodium and plasma osmolality had returned to normal and
there were no clinical signs of dehydration”.
Duration of fluid therapy
TheDuke 2002 study administered fluids for 48 hours; the Powell
1990 study administered fluids for 24 hours; and the Singhi 1995
study administered fluids for 24 hours, with a gradual increase
thereafter until children in both arms received the full normal
maintenance requirement after 48 hours.
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2. Baseline characteristics of participants
Age
All studies included only children. Duke 2002 included children
between one month and 12 years of age, Powell 1990 included
children between three months and 16 years, and Singhi 1995
included children between two months and seven years of age.
Health status
The children in the study carried out in Papua New Guinea were
from a population in which 25%were undernourished at the time
of their presentation (Duke 2002). In regard to the meningitis
symptoms, themean duration of symptomswas six days, with two-
thirds of children having convulsions, before presentation; 20%
of the children were hypoglycaemic.
The Powell 1990 study gave no specific details, but said that they
only enrolled “previously healthy children”. Malnourished chil-
dren were excluded from the Singhi 1995 study, and children had
a duration of symptoms ranging from one to 10 days on presen-
tation.
Diagnostic techniques used to establish a diagnosis of
bacterial meningitis
The Duke 2002 study made a diagnosis according to clinical signs
ofmeningitis and a cloudy or turbid cerebrospinal fluid (CSF)with
a moderate or large number of leucocytes and amount of protein,
determinedby dipstick testing (Multistix 10SG).The Powell 1990
study diagnosed meningitis on the basis of clinical examination,
CSF cytology, and chemical studies. The Singhi 1995 study made
a diagnosis on a suggestive history, physical examination, CSF
findings of hypoglycorrhachia, increased protein concentration,
and polymorphonuclear leucocytosis.
3. Studied outcomes
Death
Two studies reported death as an outcome (Duke 2002; Singhi
1995). Personal communication with the lead author of the Powell
1990 study reported no fatalities.
Short-term (within the first four weeks of illness) and long-
term (persisting after the first four weeks of illness)
neurological sequelae
Two studies reported acute neurological sequelae (Duke 2002;
Singhi 1995). One of these studies also reported individual neuro-
logical components at 14 days (spasticity, hemiparesis/hemiplegia,
visual impairment, and no response to sound) and neurological
sequelae at three months (Duke 2002).
Seizures
Duke 2002 reported the incidence of seizures at both 72 hours
and 14 days. In the 2014 update of this review, ’seizures’ was
not treated as a separate secondary outcome since this outcome is
already captured within the primary outcome ’acute (short-term)
neurological sequelae’.
Oedema (including cerebral)
One study reported facial oedema, pulmonary oedema, and hy-
drocephalus (Duke 2002).
Total body water
One study reported total body water as an outcome (Singhi 1995).
Extracellular water
One study reported extracellular water as an outcome (Singhi
1995).
Serum and urinary sodium
Two studies reported comparisons of mean serum-sodium con-
centrations (Powell 1990; Singhi 1995). Duke 2002 reported the
proportion of children with serum-sodium concentrations below
130 mmol/litre at 72 hours. One study reported urinary sodium
as an outcome (Singhi 1995).
Plasma and urinary osmolality
One study reported plasma and urinary osmolality as an outcome
(Singhi 1995).
Duration of hospital stay
No study reported duration of hospital stay as an outcome.
Raised intracranial pressure
No study reported on raised intracranial pressure.
Status epilepticus
No study reported on incidence of status epilepticus.
Excluded studies
We excluded three studies as they were not RCTs (Brown 1994;
Duke 1998; Floret 1999), one study because the interventions and
comparators were not relevant (Berkley 2004), and another study
because insufficient data on culture-positive bacterial meningitis
were available (Maitland 2013).
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Risk of bias in included studies
A graphical representation of the risk of bias for the included
studies is shown in Figure 1. A summary of methodological quality
of the included trials is given in Figure 2.
Figure 1. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Two studies used opaque, sealed, sequentially-numbered envelopes
(Duke 2002; Powell 1990). The remaining study used a random
numbers table (Singhi 1995) and judged to have low risk. Two
trials displayed adequate allocation concealment (Duke 2002;
Powell 1990). The quality of allocation concealment in the third
study was unclear (Singhi 1995).
Blinding
Performance bias
Blinding of participants and personnel was high risk for all trials
Detection bias
This was judged to be low risk for all the three trials for the out-
comes of death and acute severe neurological sequelae as clinically
they are quite objective and obvious even though no blinding was
done.Since no blinding was done for outcome assessment it would
be high risk for the outcome of chronic sever neurological sequale
where the clinical manifestation would not be so obvious.
Attrition bias
The attrition bias was found to be low risk for two trials (Duke
2002; Singhi 1995) and high risk for one (Powell 1990).
Reporting bias
Reporting bias was found to be high risk in two studies (Powell
1990; Singhi 1995) and low risk in one study (Duke 2002).
Power calculations
Two studies documented power calculations (Duke 2002; Singhi
1995). Duke 2002 calculated a required participation of 354 to
detect a one-third reduction in adverse outcomes. The study ran-
domised 357 children and analysed results for 346 children im-
mediately at completion of treatment. Singhi 1995 calculated that
31 children in each group were needed to detect a 25% change
in intact survival rate from 50%, with a significance of 0.05. This
study was terminated early, but enrolled 25 in each group.
Number of centres
Duke 2002 had three participating centres. The remaining two
were single-centre studies (Powell 1990; Singhi 1995).
Intention-to-treat (ITT) analysis
No study reported an ITT analysis.
Incomplete outcome data
The largest study had relatively small numbers of dropouts (11
of 357 enrolled children) by the end of treatment, when most of
the outcomes were measured (Duke 2002). By three months from
diagnosis there were over 10% dropouts.
The Powell 1990 study had five exclusions from 24 children en-
rolled, and this would have introduced the possibility of signifi-
cant bias. Singhi 1995 had no dropouts.
Selective reporting
There was no evidence of selective reporting of data in Duke
2002; both short-term and longer-termmorbidities were reported.
Powell 1990 only reported short-term sodium levels. Singhi 1995
only reported total numbers with short-term neurological impair-
ment and did not attempt to break these down by type of impair-
ment.
Other potential sources of bias
Themain concern was themarked discrepancy in size between the
largest study and the two other very small RCTs. The Singhi 1995
trial was stopped prematurely owing to observance of “a trend
toward poor outcome in the restricted-fluid group”, and this is
also a potential source of bias.
Effects of interventions
See: Summary of findings for the main comparison
Maintenance fluids versus restricted fluids for acute bacterial
meningitis
Primary outcomes
1. Death
All participants, regardless of serum sodium at enrolment
The meta-analysis of the three studies (420 children) for deaths
(Duke 2002; Powell 1990; Singhi 1995), where one study reported
no fatality amongst their participants (Powell 1990), found no sig-
nificant difference between deaths in the maintenance-fluid and
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restricted-fluid groups; risk ratio (RR) 0.82, 95%confidence inter-
val (CI) 0.53 to 1.27; low quality evidence (Summary of findings
for the main comparison; Analysis 1.1.1).
Participants with or without hyponatraemia
The Singhi 1995 study that subdivided maintenance-fluid and re-
stricted-fluid groups into children with or without hyponatraemia
at presentation found no significant difference in death rates in
either those presenting with hyponatraemia (26 children) or those
without hyponatraemia (24 children). With hyponatraemia, the
RR for children given the two different fluid intakes was RR 0.15,
95% CI 0.01 to 2.50 (Analysis 1.1.2); without hyponatraemia,
the RR was 0.79, 95% CI 0.16 to 3.90 (Analysis 1.1.3).
2. Short-term (within the first four weeks of illness) and
long-term (persisting after the first four weeks of illness)
neurological sequelae
Short-term neurological sequelae
The meta-analysis of acute severe neurological sequelae (2 studies,
407 children) found no significant difference between the mainte-
nance-fluids and restricted-fluids groups (RR 0.67, 95% CI 0.41
to 1.08; low quality evidence) (Summary of findings for the main
comparison; Analysis 1.2.1).
Data on mild to moderate sequelae at 14 days (1 study, 357 chil-
dren) also showed no significant difference between maintenance-
fluid and restricted-fluid groups (RR 1.24, 95% CI 0.58 to 2.65)
(Analysis 1.3.1).
However, when neurological sequelae were categorised further, the
available data produced the following results.
• Hemiparesis/hemiplegia (1 study, 357 children): no
significant difference between groups (RR 0.97, 95% CI 0.52 to
1.81) (Analysis 1.4.1).
• Spasticity (1 study, 357 children): there was a statistically
significant difference in favour of the maintenance-fluid group
(RR 0.50, 95% CI 0.27 to 0.93) (Analysis 1.5.1).
• Seizures (1 study, 357 children): there was a statistically
significant difference in seizure activity at both 72 hours (RR
0.59, 95% CI 0.42 to 0.83) and 14 days (RR 0.19, 95% CI 0.04
to 0.88) in favour of the maintenance-fluid group (Analysis 1.6).
• Visual impairment and response to sound (1 study, 357
children): there was no statistically significant difference in either
group. On visual impairment the RR was 0.77, 95% CI 0.44 to
1.35 (Analysis 1.7) and on response to sound, RR 0.60, 95% CI
0.25 to 1.41 (Analysis 1.8).
Participants with or without hyponatraemia
Analyses of data from participants with and without hypona-
traemia at presentation showed no significant difference in acute
neurological sequelae for either subgroup. Without hypona-
traemia, the RR for children given maintenance fluids or restricted
fluids was RR 0.59, 95% CI 0.13 to 2.64 (Analysis 1.2.3); with
hyponatraemia, RR 0.91, 95% CI 0.34 to 2.47 (Analysis 1.2.4).
Long-term neurological sequelae
The data relating to chronic severe neurological sequelae (1 study,
351 children) showed a statistically significant difference at three-
month follow-up in favour of those in the maintenance-fluid
groups: RR 0.42, 95% CI 0.20 to 0.89; very low quality evidence
(Summary of findings for the main comparison; Analysis 1.2.2).
Secondary outcomes
1. Oedema (including cerebral)
The data on facial oedema (1 study, 357 children) showed a statisti-
cally significant difference in favour of the restricted-fluids group:
RR 5.47, 95% CI 2.65 to 11.27. There was no statistically sig-
nificant difference in either pulmonary oedema (RR 8.75, 95%
CI 0.47 to 161.38) or hydrocephalus (RR 0.28, 95% CI 0.06 to
1.32) (Analysis 1.9).
2. Total body water
The data on change in total body water at 48 hours after admis-
sion (1 study; 24 children without hyponatraemia, 26 children
with hyponatraemia) showed a statistically significantly greater re-
duction in the restricted-fluids group in both non-hyponatraemic
and hyponatraemic children: mean difference (MD) (meq/litre)
24.50, 95% CI 9.91 to 39.09; and MD (meq/litre) 36.00, 95%
CI 19.83 to 52.17, respectively (Analysis 1.10).
3. Extracellular water
The data on reduction in extracellular water at 48 hours after ad-
mission (1 study; 24 children without hyponatraemia, 26 chil-
dren with hyponatraemia) showed a greater reduction in the re-
stricted-fluid groups: non-significant for non-hyponatraemic chil-
dren: MD (meq/litre) 22.90, 95% CI -1.11 to 46.91; and a statis-
tically significant change in hyponatraemic children: MD (meq/
litre) 35.00, 95% CI 16.86 to 53.14 (Analysis 1.11).
4. Serum and urinary sodium
Duke 2002 reported the proportion of children with serum
sodium concentrations below 130 mmol/litre at 72 hours and
found no statistically significant difference between the restricted-
fluid and maintenance-fluid groups: RR 0.72, 95% CI 0.34 to
1.55 (Analysis not shown).
13Fluid therapy for acute bacterial meningitis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
We did not attempt a meta-analysis of the two studies compar-
ing mean sodium concentrations, as Powell 1990 measured serum
sodium at 24 hours and Singhi 1995, at 48 hours. The Powell
1990 study (13 children with bacterial meningitis) reported all
children together and found no statistically significant difference
inmean serum sodium at 24 hours: MD (meq/litre) 3.00, 95%CI
-0.94 to 6.94. The Singhi 1995 study (1 study; 24 children with-
out hyponatraemia, 26 children with hyponatraemia) subgrouped
children by hyponatraemia status at study entry. The study found
a statistically significant difference in favour of the restricted-fluid
group in children with hyponatraemia (MD (meq/litre) -4.20,
95% CI -6.20 to -2.2). In the original paper, the statistical dif-
ference in favour of restricted fluids in children without hypona-
traemia (MD (meq/litre) -3.50, 95% CI -7.58 to 0.58, P = 0.09)
was reported as statistically significant, but this is not the case,
as evident from examination of the effect estimate and the 95%
CI. This study also found a significant difference in the change
in serum sodium from baseline, in favour of the restricted-fluid
group, in children both with and without hyponatraemia. With-
out hyponatraemia, the MD (meq/litre) was -5.8, 95% CI -11.59
to -0.01; with hyponatraemia, MD (meq/litre) -4.40, 95% CI -
6.97 to -1.83 (Analysis 1.12).
The one study (24 children without hyponatraemia at admission,
26 children with hyponatraemia) that reported urinary sodium
foundno significant difference at 48hours inmeanurinary sodium
in children without hyponatraemia (MD (meq/litre) -14.0, 95%
CI -31.60 to 3.6) but a statistically significant difference in chil-
dren with hyponatraemia at admission (MD (meq/litre) -21.00,
95% CI -34.14 to -7.86). There was no significant change from
baseline at 48 hours either in children without hyponatraemia
(MD (meq/litre) 1.00, 95% CI -12.22 to 14.22) or with hypona-
traemia (MD (meq/litre) 0.0, 95% CI -8.94 to 8.94) (Analysis
1.13).
5. Plasma and urinary osmolality
There was a statistically significant difference in the change in
plasma osmolality after 48 hours, with a greater increase in the
restricted-fluid group, in both the children presenting without
hyponatraemia (1 study, 24 children):MD (meq/litre) -5.00, 95%
CI -9.82 to -0.18; and children presenting with hyponatraemia (1
study, 26 children): MD (meq/litre) -6.00, 95% CI -11.36 to -
0.64 (Analysis 1.14).
6. Duration of hospital stay
No study reported on duration of hospital stay.
7. Raised intracranial pressure
No study reported on raised intracranial pressure.
8. Status Epilepticus
No study reported on incidence of status epilepticus.
D I S C U S S I O N
Summary of main results
The small number of studies identified by this review did not show
any statistically significant difference in mortality or acute severe
neurological sequelae from restricting fluids. Two studies reported
high mortality rates overall, well above 10% (Duke 2002; Singhi
1995; 407 children). The third study included very small numbers
(19 children analysed), and reported no deaths (Powell 1990).
Meta-analysis of the two studies reporting neurological sequelae
demonstrated statistically significant reductions in the rates of early
spasticity and seizures, and later overall neurological sequelae, in
children receiving maintenance fluids. There were no statistically
significant differences in overall short-term neurological sequelae
or in risk of hemiparesis, visual, or hearing impairment.
Two of the studies involved very small numbers of children from
single centres (Powell 1990; Singhi 1995). Themortality andmor-
bidity results, therefore, are dominated by the Duke 2002 study.
The long delays before presentation and a high rate of malnutri-
tion in the children in this study may have been associated with a
high rate of dehydration at presentation. The finding of a higher
rate of neurological sequelae in the restricted-fluid group in this
study could result from inadequate initial treatment of dehydra-
tion. This might not be relevant in settings where patients present
earlier.
Overall completeness and applicability of
evidence
The three included studies were insufficient to evaluate the review
objective of evaluatingdifferent volumes of initial fluid administra-
tions on treatment outcomes of acute bacterial meningitis. We did
not find any trial answering the review question for adult patients.
All the trials were conducted in in-hospital settings and no trials
were carried out in primary care or out-of-hospital settings, where
initial fluid therapy is often instituted, and the patients referred
to a tertiary care set-up for specialised care. Trials done in out-of-
hospital and primary healthcare settings might be more relevant
to low- and middle-income nations, where healthcare delivery is
not well monitored, and generally unstructured (Maher 2011).
The largest of the three studies included multiple outcomes rele-
vant to the review question (Duke 2002). Its shortcoming was that
it could only address the question in settings with high mortality
and morbidity rates and long delays before presentation.
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The other two included studies were too small to allow any con-
clusions to be drawn. None of the studies included adults.
The results of short-term fluid and electrolyte balance do not in
themselves provide adequate evidence onwhich to change practice.
The reporting of sodium levels was inconsistent so that it was not
possible to undertake a meta-analysis.
The quality of evidence for the primary and secondary outcomes
was low to very low and thus insufficient to guide clinical practice.
Quality of the evidence
We assessed the overall quality of the evidence using the GRADE
approach (Schunemann 2011), as shown in Summary of findings
for the main comparison. The overall quality of the evidence
for maintenance-fluid versus restricted-fluid regimens for children
with acute bacterial meningitis was low for the outcomes of death,
and acute severe neurological sequelae, and very low for chronic
severe neurological sequelae. In this 2016 update we revised the
GRADE table to reflect current Cochrane standards, and improve
clarity and consistency of reporting results.
Potential biases in the review process
We searched a number of electronic databases using a number of
search terms. We expect that our search strategy has been success-
ful in identifying all relevant studies. Standard Cochrane method-
ologies have been used to minimise any bias in the review process.
Agreements and disagreements with other
studies or reviews
There are no systematic reviews which have explored this research
question.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is a lack of high quality evidence to guide the use of fluid
therapy for acute bacterial meningitis. There are no trials in adult
or elderly populations; all trials were in children. The meta-analy-
sis found no significant difference between the maintenance-fluid
and restricted-fluid groups in number of deaths (low quality of
evidence), or acute severe neurological sequelae (low quality of
evidence). Some evidence was found favouring maintenance fluid
over restrictive regimens for the outcome of chronic severe neu-
rological sequelae events at three months follow-up, although the
quality of evidence is very low and hence not enough to guide
practice. Most of the evidence was from high mortality setting.
Implications for research
Future randomised clinical trials should evaluate maintenance
fluid versus restricted fluid for acute bacterial meningitis. Trials
in adult populations, particularly elderly populations, are needed
and in countries with high and lowmortality rates for acute bacte-
rial meningitis. Large, high quality trials are also needed to assess
the effectiveness of either restricting or administeringmaintenance
fluids in populationswhere people present early andwheremortal-
ity rates are low. Trials also need to focus on important outcomes
such as duration of hospital stay and raised intracranial pressure.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Duke 2002
Methods Setting: Hospital Inpatient department
Study design: Randomised, parallel group, multi-centre, controlled trial
Location: Papua New Guinea
Timing and duration: September 1997 to October 2000
Number of centres: 3
Source of funding: Roche, World Health Organization, and Royal Australasian College
of Physicians
Participants Children with clinical signs of meningitis, cloudy or turbid CSF with moderate or large
amounts of leucocytes and protein on dipstick testing (Multistix 10 SG) were eligible
for inclusion. Children with renal failure, congenital heart disease, who had received
parenteral antibiotics for 48 hours or more in the week prior to presentation or who
were septic or in hypovolaemic shock were excluded from enrolment
Age: > 1 month to < 12 years
Interventions Nasogastric tube fluids at 60% of maintenance fluids, (maintenance fluids defined by
“100 ml/kg/day for the first 10 kg of body weight, 50 ml/kg for the second 10 kg, and
20 ml/kg for over 20 kg”) as expressed breast milk or other milk feed, divided into feeds
given every 3 hours
versus
100%of normalmaintenance fluids (defined as above) administered intravenously (given
nasogastrically in 7 children because an intravenous cannula could not be inserted) given
as a solution containing 0.45% sodium chloride and 5% dextrose plus 10 mmol/L of
potassium chloride per litre
Duration: 48 hours
Outcomes Death
Neurological sequelae
Oedema (including cerebral)
Serum and urinary sodium
Seizures
Notes 260 of the 357 children had confirmed bacterial meningitis. The paper states that al-
though no bacteria were isolated in the other children the diagnosis was “definitely
meningitis”. Numbers of children without isolated bacteria was similar between groups
Severe sequelae were considered to be present if 14 days after commencing treatment
there was a severe motor deficit (marked spasticity, hemiplegia, severe hypotonia) and at
least one of the following: a major sensory deficit (inability to fix and follow in an age-
appropriate way or no response to sound), persistent convulsions or coma
All children received phenobarbitone, and received oxygen for the first 48 hours. The
1st 150 children received chloramphenicol, the rest ceftriaxone. Mechanical ventilation
was not available
Risk of bias
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Duke 2002 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Adequate, with comparable treatment and
control groups at entry
Allocation concealment (selection bias) Low risk Adequate, using sealed envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Clearly not
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Low risk for outcomes of death and acute
severe neurological sequelae
Incomplete outcome data (attrition bias)
All outcomes
Low risk Adequate overall with 11 of 357 excluded
post-randomisation as found not to have
meningitis. However, over 10% of partici-
pants lost to follow-up at 3 months
Selective reporting (reporting bias) Low risk Adequate, with a good range of appropriate
outcomes reported. 14 days is somewhat
early to judge whether severe sequelae were
present
Other bias Low risk A large and well-described study
Powell 1990
Methods Setting: Hospital Inpatient department
Study design: Randomised, parallel group, single-centre, controlled trial
Location: USA
Timing and duration: July 1985 to June 1988
Source of funding: Hoffmann-La Roche, Praxis Biologies, National Institute of Health
Participants Previously healthy childrenwith a clinical diagnosis ofmeningitis, and confirmed byCSF
cytology and by chemical studies were eligible for inclusion. Children with central ner-
vous system disease, renal disease, who were prematurely delivered (at less than 36 weeks
gestation), who have congestive heart failure, chronic pulmonary disease, malignancy,
immunodeficiency, hepatic disease, or were on morphine/phenobarbitone/phenytoin/
dexamethazone or lithium were excluded from enrolment
Age: 3 months to 16 years
Interventions 2/3 maintenance fluids (maintenance defined as 100 ml/kg for the first 10 kg of body
weight, plus 50 ml/kg for the next 10 kg (10 kg to 20 kg), plus 20 ml/kg for each
kilogram in excess of 20 kg)
versus
Full maintenance fluids (as defined above), plus replacement fluids for any estimated
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Powell 1990 (Continued)
deficit over 24 hours. Rehydration was begun by administering 10 ml/kg or 15 ml/kg
by rapid intravenous infusion
Duration: 24 hours
Outcomes Serum osmolality
Serum sodium
Notes 13 children with bacterial meningitis and 6with aseptic meningitis were enrolled. Results
were reported separately. However, the initially pathology of the 6 exclusions was not
documented
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Low risk Adequate, using sealed envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Clearly not
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Low risk for outcomes of death and acute
severe neurological sequelae
Incomplete outcome data (attrition bias)
All outcomes
High risk Did not account for all participants. 5 out
of 24participantswere not included in final
analysis
Selective reporting (reporting bias) High risk Reporting of outcome data not adequate.
No reporting of important outcomes of
death, intact survival
Other bias High risk Most eligible participants not randomised.
Poor reporting of details of study
Singhi 1995
Methods Setting: Hospital Inpatient department
Study design: Randomised, parallel group, single-centre, controlled trial
Location: India
Timing and duration: not stated
Source of funding: not stated
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Singhi 1995 (Continued)
Participants Children with a diagnosis of bacterial meningitis were eligible for inclusion. Chil-
dren with heart disease, respiratory illness, gastrointestinal disease, renal disease, cen-
tral nervous system disease, malnutrition (less than 60% of weight expected for age),
endocrinopathy, malignancy, immunodeficiency, or who had received previous anticon-
vulsant therapy were excluded
Age: 2 months to 7 years
Interventions 65% calculated maintenance fluid requirement, given as intravenous 1/5th normal saline
in 5% dextrose for 24 hours, followed by “a gradual liberalisation at a rate of 10 ml/
kg/8 hours after 24 hours of hospital stay if serum sodium and plasma osmolality had
returned to normal and if there were no clinical signs of dehydration versus maintenance
fluid requirements (110 ml/kg for first 10 kg, 50 ml/kg for next 10 kg and 25 ml/kg for
subsequent weight) given as intravenously and comprising 1/5th normal saline in 5%
dextrose” as long as they required intravenous fluids
Outcomes Intact survival with sequelae
Death
Total body water
Extracellular water
Serum sodium plasma osmolality
Urine sodium
Urine osmolality
Notes Trial was stopped prematurely “when a trend toward poor outcome in the restricted-
fluid group became obvious”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Use of a list or table. Treatment and control
groups were comparable at study entry
Allocation concealment (selection bias) Unclear risk Unclear, with the use of a list or table
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Clearly neither participant’s nor treatment
providers blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Clearly neither outcome assessors, partici-
pants nor treatment providers blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Appeared to account for all participants
Selective reporting (reporting bias) High risk Mixed neurological outcomes and compli-
cations, so some important outcomes un-
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Singhi 1995 (Continued)
available
Other bias High risk Study was stopped prematurely, with no a
priori stopping rules, with a “trend towards
poor outcome” in one group
CSF: cerebrospinal fluid
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Berkley 2004 Interventions and comparators not relevant
Brown 1994 Not a RCT
Duke 1998 Not a RCT
Floret 1999 Not a RCT
Maitland 2013 Sufficient data on culture-positive bacterial meningitis not available
Pelkonen 2011 Intervention not relevant
Roine 2014 Not a RCT; used for reference searching for a trial mentioned in abstract which was found to be Pelkonen 2011
van Paridon 2015 Not a RCT
RCT: randomised controlled trial
22Fluid therapy for acute bacterial meningitis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
D A T A A N D A N A L Y S E S
Comparison 1. Maintenance fluids versus restricted fluids
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 All participants 2 407 Risk Ratio (M-H, Fixed, 95% CI) 0.82 [0.53, 1.27]
1.2 Participants with
hyponatraemia
1 26 Risk Ratio (M-H, Fixed, 95% CI) 0.15 [0.01, 2.50]
1.3 Participants without
hyponatraemia
1 24 Risk Ratio (M-H, Fixed, 95% CI) 0.79 [0.16, 3.90]
2 Severe neurological sequelae 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 Acute (within the first 4
weeks)
2 407 Risk Ratio (M-H, Fixed, 95% CI) 0.67 [0.41, 1.08]
2.2 Chronic (after the first 4
weeks)
1 351 Risk Ratio (M-H, Fixed, 95% CI) 0.42 [0.20, 0.89]
2.3 Participants without
hyponatraemia
1 24 Risk Ratio (M-H, Fixed, 95% CI) 0.59 [0.13, 2.64]
2.4 Participants with
hyponatraemia
1 26 Risk Ratio (M-H, Fixed, 95% CI) 0.91 [0.34, 2.47]
3 Mild to moderate neurological
sequelae
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
3.1 At 14 days 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Hemiparesis/hemiplegia 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
4.1 At 14 days 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Spasticity 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
5.1 At 14 days 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Seizures 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
6.1 Within the first 72 hours 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.2 At 14 days 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7 Visual impairment 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
7.1 At 14 days 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8 No response to sound 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
8.1 At 14 days 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
9 Oedema 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
9.1 Acute facial oedema 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
9.2 Acute pulmonary oedema 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
9.3 Acute hydrocephalus 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
10 Total body water - fall after 48
hours
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
10.1 Participants without
hyponatraemia
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
10.2 Participants with
hyponatraemia
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
11 Extracellular water - fall after
48 hours
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
11.1 Participants without
hyponatraemia
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
23Fluid therapy for acute bacterial meningitis (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
11.2 Participants with
hyponatraemia
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
12 Serum sodium 2 Mean Difference (IV, Fixed, 95% CI) Totals not selected
12.1 All participants (24
hours)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
12.2 Participants with
hyponatraemia (48 hours)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
12.3 Participants without
hyponatraemia (48 hours)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
12.4 Change from baseline
at 48 hours - without
hyponatraemia
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
12.5 Change from baseline at
48 hours - with hyponatraemia
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
13 Urinary sodium 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
13.1 Participants without
hyponatraemia (48 hours)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
13.2 Participants with
hyponatraemia (48 hours)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
13.3 Change from baseline
at 48 hours - without
hyponatraemia
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
13.4 Change from baseline at
48 hours - with hyponatraemia
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
14 Plasma osmolality - change
after 48 hours
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
14.1 Participants without
hyponatraemia
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
14.2 Participants with
hyponatraemia
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
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F E E D B A C K
Feedback on ’Fluid therapy for acute bacterial meningitis’, 13 February 2013
Summary
In your review, you present separate analyses of ‘acute severe sequelae’, ‘chronic severe sequelae’, and ‘mild to moderate sequelae’ of
bacterial meningitis.
I can’t find anything in the review to tell me which sequelae are included under acute severe, which under chronic severe, and which
under mild to moderate. The neurological sequelae described in the review seem quite severe to me: hemiparesis/hemiplegia, spasticity,
seizures, visual impairment and impaired response to sound. I can’t see anything that I would consider moderate but that is just my
own opinion rather than being based on any external awareness of how sequelae are categorized. I also can’t be sure what the different
sequelae are that occur within 4 weeks (acute) and after 4 weeks (chronic) - is it the same sequelae manifesting at different times or
would different sequelae appear acutely and chronically?
I think these data would be very valuable to understanding the clinical import of the different meta-analyses that you present.
I agree with the conflict of interest statement below:
I certify that I have no affiliations with or involvement in any organization or entity with a financial interest in the subject matter of
my feedback.
Karen Pettersen
Affiliation: Wiley-Blackell
Role: Editor, Cochrane Clinical Answers
Reply
The classification of acute and chronic is based onwhether the sequelae effect persist after the first four weeks of illness or not, irrespective
of the type of sequelae. The classification into severe and mild to moderate is as per the limited information available from the studies
available and the reporting is only to aid the reader by producing such categorisation. There is no widely accepted categorisation for
neurological sequelae of meningitis.
Contributors
Ian Maconochie and Soumyadeep Bhaumik
WH A T ’ S N E W
Date Event Description
21 March 2016 New search has been performed Searches updated. We did not identify any new trials for
inclusion. We excluded three new trials (Pelkonen 2011;
Roine 2014; van Paridon 2015).
21 March 2016 New citation required and conclusions have changed We reworked the GRADE profile and updated it as per
current Cochrane standards. The conclusion with regards
to quality of evidence has changed
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H I S T O R Y
Date Event Description
5 November 2013 New search has been performed Seizures are capturedwithin the primary outcome acute
(short-term) neurological sequelae and consequently
have now been removed from the list of secondary out-
comes
No new trials were included in this update. Two new
trials initially considered were excluded (Berkley 2004;
Maitland 2013). In this update we have used the
GRADE approach to interpret the findings and these
have been updated. This provides critically important
information for healthcare decision-making. This up-
date also takes into account the newMECIR standards
5 November 2013 New citation required but conclusions have not
changed
A new review author joined to help update this review.
14 June 2013 Feedback has been incorporated Feedback added.
9 August 2010 New search has been performed Searches conducted. No new trials were included or
excluded in this update
19 May 2008 Amended Converted to new review format.
1 March 2007 New search has been performed Searches conducted.
17 March 2005 New search has been performed Searches conducted.
C O N T R I B U T I O N S O F A U T H O R S
IanMaconochie (IM) jointly (with Richmal Oates-Whitehead (ROW)) conceptualised the review, commented on drafts of the protocol,
was involved in selecting trials for inclusion in the review, performed independent data extraction and quality assessment of the included
trials.
Soumyadeep Bhaumik (SB) led this 2016 update and was part of the 2014 update. For both updates he performed independent
selection of trials for inclusion in the review, worked on the manuscript of the review. Both authors used the GRADE approach to
interpret the findings of the study and commented on the drafts of the review.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
There were insufficient data to explore any of the subgroup analyses, with the exception of hypoperfusion at entry.One study subgrouped
each participant group into those with hyponatraemia and those without hyponatraemia at enrolment (Singhi 1995). Therefore, we
could only perform a subgroup analysis on this trial.
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